GSK Glaxo Smith

GSK’s Blenrep returns to the US market after FDA approves resubmission

FDA · blood cancer · 5 min

The FDA has approved GSK’s Blenrep in combination with bortezomib and dexamethasone, clearing the drug’s return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.

Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response

FDA · COVID-19 · 6 min

Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.

GSK Blenrep wins FDA approval in relapsed multiple myeloma

FDA · blood cancer · 6 min

GSK’s Blenrep has returned to the U.S. market after the FDA approved it in combination with bortezomib and dexamethasone for relapsed or refractory multiple myeloma. The catalyst matters for BD teams and investors because it reverses a prior withdrawal and resets the drug’s U.S. label and commercial outlook.

Friday Five: Key Regulatory Updates in Pharma

FDA · hepatitis · 3 min

This article covers significant regulatory updates impacting the pharmaceutical industry, including GSK's breakthrough in hepatitis B and Eli Lilly's advancements in prevention.

GSK and Ionis Present Promising Hepatitis B Drug Data

hepatitis · 2 min

GSK and Ionis have unveiled significant data on their hepatitis B drug, presenting a potential functional cure. This development could reshape treatment strategies in the pharmaceutical industry.

GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition

3 min

GSK and Alfasigma have entered a licensing agreement for Linerixibat, while Servier has finalized a $2.5 billion acquisition of Day One Pharmaceuticals. This article explores the implications for the pharmaceutical landscape.

AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma

2 min

AbbVie and GSK have made significant strides in patient reputation in the UK. This article explores the implications for the pharmaceutical industry.